Athira Pharma renames to LeonaBio (LONA); lasofoxifene Phase 3 >50% enrolled; CFO gets new severance

LeonaBio, Inc.

Name change to LeonaBio effective Jan 9, 2026; ticker to LONA on Nasdaq starting Jan 12.
Phase 3 ELAINE-3 trial of lasofoxifene >50% enrolled; topline data expected mid-2027.
CFO Robert Renninger entered amended change in control severance agreement; base salary increased to $460,000.
Name change reflects Dec 2025 acquisition of lasofoxifene rights, with $90M upfront financing and potential additional $146M.

item 5.03 item 7.01 item 8.01 item 5.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

LeonaBio, Inc.: Certificate of Amendment to Amended and Restated Certificate of Incorporation to change corporate name from Athira Pharma, Inc. to LeonaBio, Inc (effective 2026-01-09).

Change: charter amendment
Effective: 2026-01-09

Exact text from the filing

Effective January 9, 2026, Athira Pharma, Inc. (the “Company”) changed its name to LeonaBio, Inc. (the “Name Change”). The Name Change was approved by the Company’s Board of Directors (the “Board”) and was effectuated through the filing of a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Amended and Restated Certificate of Incorporation with the Delaware Secretary of State.

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

LeonaBio, Inc.: Amended and restated bylaws to reflect the name change to LeonaBio, Inc (effective 2026-01-09).

Change: bylaw amendment
Effective: 2026-01-09

Exact text from the filing

Additionally, effective January 9, 2026, the Board approved an amendment and restatement of the Company’s bylaws (the “Amended and Restated Bylaws”) to reflect the Name Change.

View on SEC.gov

Browse all governance changes →

LeonaBio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-008904

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.